Datamonitor Healthcare

Introduction

BRAND NEW: Our pipeline report now contains an interactive early-phase forecast model and a chapter on early-phase opportunities within asthma – exclusive content you’ll only find at Datamonitor Healthcare.

Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated. Biologics in the pipeline for asthma aiming to treat this patient population. Datamonitor Healthcare has provided an in-depth analysis of pipeline products in the US, Japan and five major EU markets, including new clinical data and an evaluation of clinical and commercial drug attributes.

Click here to download your free Table of Contents >>
Click here to download your free Sample Pages >>

How will our asthma pipeline report benefit you?

Target unmet needs
Understand which populations in asthma are inadequately treated and how late-stage therapies will target these patient groups, enabling you to identify where there is still room for opportunities and what needs are currently being overlooked.
Identify investment opportunities
Explore the future developments in the treatment of asthma, understanding how once-daily fixed-dose inhalers such as Breo will change therapy and how asthma therapy will progress, allowing you to identify what therapies you should be investing in to gain potential commercial success within the market.
Gain competitive overview
Understand how biologics will position themselves within the market and compete against each other by comparing their clinical and commercial attributes, allowing you to benchmark your product against that with the most potential for success.
Identify early-phase opportunities
Access our exclusive interactive 20-year early-phase forecast model with clearly identified opportunities to assist in your decision-making.

Key questions answered: